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Executive Summary
Prescription drug monitoring programs (PDMPs) are state policy tools to combat risky
opioid prescribing. Since 2012, several states began to mandate PDMP use. As mandating use
laws have settled down, evaluating potential adverse events becomes possible.
In this study, I focus on alcohol-induced mortality as a potential unintended consequence
via substituting alcohol for prescription opioids, since alcohol and opioids are often concurrently
misused as a part of pain self-management. Therefore, the aim of this study is to analyze the
unintended consequences of prescription opioid access restrictions on alcohol-induced mortality.
I compare the alcohol-induced mortality among adults during pre- and post-revision of
the Kentucky PDMP from 2007 to 2017 by using a difference-in-differences design. The countylevel alcohol-induced death data was extracted from Centers for Disease Control and Prevention
Wide-ranging Online Data for Epidemiologic Research. Missouri was chosen as a comparison
state because state-level PDMP have not been existed.
The finding indicated that mandating PDMP use in Kentucky did not enhance alcoholinduced mortality. In conclusion, prescription opioid access restrictions do not appear to result in
unintended consequences on alcohol-induced mortality for adults. Therefore, I recommend
retaining the mandatory features of Kentucky’s PDMP. This study is the first assessment of
alcohol-related adverse events resulting from PDMPs. Further studies should be conducted to
evaluate the finding.
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Introduction
Opioid Crisis: Pain Management Failure
During the 1990s, the healthcare system experienced a renewed focus on pain
management. The American Pain Society and the United States Department of Veterans Affairs
promoted pain as the ‘fifth vital sign’, along with body temperature, blood pressure, pulse, and
respiratory rate. Then in 2001, the Joint Commission on Accreditation of Healthcare
Organizations also adopted pain as the ‘fifth vital sign’ and certified hospitals only when pain
assessments were conducted for all patients. These institutional policies led medical providers to
making pain treatment a priority for patients (Christie, et al., 2017). This, coupled with several
publications by healthcare providers who claimed little to no addictive tendencies in their
patients after prescribing opioids—specifically a letter titled "Addiction Rare in Patients Treated
with Narcotics (Jick, 1980)" published in the New England Journal of Medicine – led medical
professionals toward opioids as a solution for the pain treatment. All the while, manufacturers of
prescription opioids, including Percocet, Vicodin, and OxyContin advertised the concept that
their medicines are safe, resulting in their prevalent use (Moghe, 2016). This frequent prescribing
of opioids for pain management continued nationally for years and contributed as a major cause
of the current opioid epidemic in the United States (U.S. Department of Health and Human
Services, 2019).
As the increased trend in opioid prescribing continued, so did deaths associated with
prescription opioids. Nearly 218,000 deaths were caused by prescription opioids from 1999 to
2017. The number of yearly deaths during this period rose rapidly, as the mortality rate in 2017
was five times as great as in 1999. In 2017, 46 people died each day due to prescription opioids.
Accordingly, among total deaths related to opioid overdose, more than 35 percent of deaths
4

involved prescription opioids. Methadone, oxycodone, and hydrocodone were the major culprit
drugs contributing to prescription opioid overdose deaths. The highest prescription opioid
induced deaths were in West Virginia, Maryland, Kentucky, and Utah (Centers for Disease
Control and Prevention, 2018). The misuse of prescribed opioids is prevalent as well. About nine
out of ten people using opioid analgesics nonmedically got the drugs from their friend/relative or
from prescriptions for themselves (Substance Abuse and Mental Health Services Administration,
2014). In 2017, 11.4 million people misused prescription opioids, including 2 million first-time
misusers (U.S. Department of Health and Human Services, 2019). Although President Trump
signed a package of bills including the Support for Patients and Communities Act to combat the
opioid crisis in October 2018 (Lopez, 2018), most states had implemented a policy solution,
namely, prescription drug monitoring programs, decades earlier to alleviate the financial,
physical, and emotional strain that was resulting from the opioid crisis.

Prescription Drug Monitoring Programs
Prescription drug monitoring programs, or PDMPs, are state-operated programs that track
the prescribing and dispensing of medications classified as federally controlled substances,
including opioids (Drug Enforcement Administration, 2018). A central system collects the
electronic prescription data, allowing only authorized users—healthcare providers, and
occasionally law enforcement—to access it. The purpose of these programs is to support the
detection and prevention of controlled substance misuse, abuse, and diversion. The program
mitigates the information asymmetry issue among healthcare providers, patients, and law
enforcement by allowing the authorized users access to patient prescription records. This
monitoring is expected to reduce the prevalence of ‘doctor shopping’, a phenomenon whereby
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patients obtain multiple prescriptions for controlled substances intentionally by visiting
numerous clinics (Blumenschein, et al., 2010; Goodin, 2015). In California, doctor shopping
occurs more often for prescription opioids than for any other controlled substances (Campbell, et
al., 2018).
PDMPs have been implemented throughout the United States, as early as 1939 in
California and as late as February 1st, 2019 in four jurisdictions of Missouri. Currently, 49 states,
the District of Columbia, Puerto Rico, Guam, and 72 jurisdictions in Missouri are operating their
own PDMPs (Brandeis University, 2018a; Saint Louis County Public Health, 2019). While most
PDMPs resemble the electronic database mentioned previously, operational details vary between
the states (Blumenschein, et al., 2010). Most early PDMPs did not legally mandate prescribers to
use the program. Consequently, the role of PDMPs in controlling prescription opioids and
opioid-associated overdose was not as effective as their intention (Haffajee, et al., 2018; Shev, et
al., 2018; Strickler, et al., 2019; Wen, Schackman, Aden, & Bao, 2017). As a result, over 40
states amended or enacted their PDMPs by adding mandatory features from 2012 to January
2019 (The Pew Charitable Trusts, 2018; Legal Science, 2016; Brandeis University, 2019).
However, the comprehensiveness of required usage by prescribers, and sometimes dispensers as
well, varies between the state programs.
Several studies described comprehensive mandatory use laws as mandates for: prescriber
enrollment, querying previous prescription opioid use history (Strickler, et al., 2019; Haffajee, et
al., 2018; Sun, et al., 2018; Brandeis University, 2019), and comprehensive use with specific
objective criteria (Haffajee, et al., 2018). Other important features of PDMPs include delegate
access (Haffajee, Jena, & Weiner, 2015; The Pew Charitable Trusts, 2018), monitoring drugs in
Schedules II to IV, more frequent data collections at regular intervals (Legal Science, 2016), and
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sharing data with other states (Brandeis University, 2018b). Among these features, the use
mandate was the most important factor improving PDMPs effectiveness on reducing mean
morphine-equivalent dosage, risky opioid prescribing, Schedule II prescriptions, and
expenditures for opioids. These studies commonly selected Kentucky, Tennessee, and New York
as states operating robust PDMPs among the early enactors of mandatory laws (Haffajee, Jena, &
Weiner, 2015; Haffajee, et al., 2018; Strickler, et al., 2019; Wen, Schackman, Aden, & Bao,
2017).
Implementation of mandatory PDMP use aroused concerns about unintended
consequences (Haffajee, Jena, & Weiner, 2015). One possible unintended consequence from
reduced access to prescription opioids is that individuals may seek alternative therapies to
substitute for the opioids that they are no longer able to obtain from their physician. In some
cases, that means the individual will seek opioids on the illicit black-market, including heroin or
synthetic opioids. In other cases, the individual may look for psychoactive substances that are
available legally (Islam & McRae, 2014; Columbia University, 2018). Alcohol is a legal
psychoactive substance that may be an attractive alternative for an individual who no longer has
access to prescription opioids. Attempts to self-medicate pain can result in unhealthy alcohol
consumption (Atkinson R. M., 1990a; Atkinson, Tolson, & Turner, 1990b). Alcohol is often used
with opioids concurrently to induce early onset of psychoactive (euphoric) effects (Maldonado,
2018; Gudin, Mogali, Jones, & Comer, 2013). Several studies argued that drinking alcohol leads
to endogenous opioid release in humans and rodents (Mitchell, Marks, Jagust, & Fields, 2012;
Gianoulakis, 2001), which implies opioid abusers could rely on more alcohol consumption to
simulate opioid use when they cannot access opioids. Therefore, the aim of this study is to
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evaluate the substitution effect, or unintended consequences, of the PDMP use mandate
implementation on alcohol-induced mortality.

Literature Review
Several studies have evaluated the early PDMPs. The opioid supply decreased in PDMPimplemented states compared to non-implemented states from 1997 to 2003 according to Drug
Enforcement Administration (DEA) data. On the other hand, PDMP implementation had no
association with lowering opioid consumption and overdose mortality rates during 1999 to 2005
in other DEA analyses (Paulozzi, Kilbourne, & Desai, 2011). In 2002, the U.S. Government
Accountability Office also reported that implementing PDMPs reduced the number of
investigation days that law enforcement officials required to detect doctor shopping in Kentucky,
which was 156 days on average before implementation and 16 days on average after
implementation (U.S. General Accounting Office, 2002).
Previous studies examining PDMPs show varying impacts. Several studies have been
conducted comparing states with PDMPs versus those without, specifically for Medicare Part D
participants. Between 2007 and 2012, states with PDMPs showed a decrease in opioid use
(Moyo, et al., 2017), while another examination between 2010 and 2013 revealed modest effects
on oxycodone use and smaller effects on opioid use (Yarbrough, 2018). PDMP and pill mill law
implementation in Florida also led to a reduction of prescription opioid utilization in high-risk
patients compared to Georgia, which had less robust policies limiting opioid access (Chang,
Murimi, Faul, Rutkow, & Alexander, 2018).
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However, some studies suggest that PDMP implementation results in a substitution effect
within the Drug Scheduling system – for example, a decrease in prescriptions for Schedule II
opioids leading to an increase in prescriptions for alternative painkillers or Schedule III drugs, so
that the overall number of prescriptions does not change significantly (Goodin, 2015; Paulozzi,
Kilbourne, & Desai, 2011; Bao, et al., 2016). In addition, recent publications found that
mandating PDMP use is related to reducing high-risk opioid prescriptions, and risk of
prescription opioid-related poisoning (Bao, et al., 2018; Pauly, Slavova, Delcher, Freeman, &
Talbert, 2018). By 2013, six states—Kentucky, New Mexico, Tennessee, New York, Vermont,
and West Virginia—strengthened their PDMPs by mandating prescribers to register with the
PDMP, and mandating comprehensive use of the program (Haffajee, et al., 2018).
A number of studies have investigated outcomes associated with PDMPs, and as
described above, findings are mixed. Surprisingly, no robust evaluation of the unintended
consequences of PDMPs currently exists. While PDMPs could be a policy solution for the
current prescription opioid problem, it is important to gauge the potentially harmful outcomes
that may result from their implementation.

Objective and Hypothesis
The goal of this project is to evaluate the potential adverse effect on alcohol-induced
mortality of prescription opioid restriction policy executed by mandating the use of PDMPs. In
this analysis, the outcome measure is specified as the change of alcohol-induced mortality among
Kentucky counties. Therefore, I hypothesized that the PDMP use mandate introduced in mid2012 increased alcohol-induced mortality in Kentucky counties after the implementation.
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Research Design
The aim of this study is to compare the alcohol-induced death rate between pre- and post2012 revision of the Kentucky PDMP from 2007 to 2017 by using a difference-in-differences
design compared with a neighboring state, Missouri, where a state-wide PDMP did not exist. The
difference-in-differences design evaluates the causal effect of a policy change on the outcome of
interest by comparing a policy-implementation group with a non-implementation group. This
analysis observed aggregated county-level data for the time period before and after
implementation. Data are annual.

State Selection
As mentioned above, Kentucky has operated an early, robust PDMP. Thus, Kentucky was
selected as a treatment state in this study. According to the Kentucky House Bill 1 (KyHB1),
prescribers and dispensers were mandated to register with the state’s PDMP and prescribers must
query the PDMP before prescribing opioids as of July 20, 2012 (Kentucky Revised Statutes
218A, 172). The policy change was immediately adopted by practitioners. In 2012, the
compliance rate of prescriber registration among DEA (Drug Enforcement Administration)
registered practitioners went up from approximately 35% to 93% after the implementation.
Moreover, the total number of queries increased more than four times after the implementation in
the same year (Freeman, Goodin, Troske, & Talbert, 2015).
I selected Missouri as a neighboring comparison state because it did not operate a statelevel PDMP during the time period. In addition, alcohol sales policy in Missouri has been
consistent throughout all counties, which will be discussed further below.
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Population and Data Source
The targeted population was 18 years or older between the time period from 2007 to
2017.
The county-level mortality data was obtained from the Centers for Disease Control and
Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER), which is a
publicly available database. In this analysis, I used detailed mortality data, which could specify
underlying cause of death.

Measure
I used alcohol-induced mortality by place of residence in Kentucky and Missouri counties
among people age 18 or more during 2007 to 2017. CDC WONDER uses the definition of
‘alcohol-induced causes’ from the National Center for Health Statistics to identify alcoholinduced mortality (Centers for Disease Control and Prevention, 2018). The definitions for
‘alcohol-induced causes’ are made using the International Statistical Classification of Diseases
and Related Health Problems, 10th revision (ICD-10) codes, which is used to categorize cause of
death by the World Health Organization. Detailed ICD-10 codes involved in this study are
presented in Table 1.
The death rate was calculated as the number of deaths per 100,000 people and was
transformed into logarithms so that estimated effects are approximately percentage changes.
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Table 1. ICD-10 codes for alcohol-induced causes
Underlying Cause of death
Alcohol-induced pseudo-Cushing syndrome
Mental and behavioural disorders due to use of alcohol, acute intoxication
Mental and behavioural disorders due to use of alcohol, harmful use
Mental and behavioural disorders due to use of alcohol, dependence syndrome
Mental and behavioural disorders due to use of alcohol, withdrawal state
Mental and behavioural disorders due to use of alcohol, withdrawal state with delirium
Mental and behavioural disorders due to use of alcohol, psychotic disorder
Mental and behavioural disorders due to use of alcohol, amnesic syndrome
Mental and behavioural disorders due to use of alcohol, residual and late-onset psychotic disorder
Mental and behavioural disorders due to use of alcohol, other mental and behavioural disorders
Mental and behavioural disorders due to use of alcohol, unspecified mental and behavioural disorder
Degeneration of nervous system due to alcohol
Alcoholic polyneuropathy
Alcoholic myopathy
Alcoholic cardiomyopathy
Alcoholic gastritis
Alcoholic fatty liver
Alcoholic hepatitis
Alcoholic fibrosis and sclerosis of liver
Alcoholic cirrhosis of liver
Alcoholic hepatic failure
Alcoholic liver disease, unspecified
Alcohol-induced acute pancreatitis
Alcohol-induced chronic pancreatitis
Finding of alcohol in blood
Accidental poisoning by and exposure to alcohol
Intentional self-poisoning by and exposure to alcohol
Poisoning by and exposure to alcohol, undetermined intent
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ICD-10 code
E24.4
F10.0
F10.1
F10.2
F10.3
F10.4
F10.5
F10.6
F10.7
F10.8
F10.9
G31.2
G62.1
G72.1
I42.6
K29.2
K70.0
K70.1
K70.2
K70.3
K70.4
K70.9
K85.2
K86.0
R78.0
X45
X65
Y15

Covariates
The policy was implemented in the middle of 2012, therefore, the years after 2012 (Post)
were coded as “1”, otherwise years are coded as “0”. I considered the latter part of 2012 as a lagphase of the policy effect and coded it as “0”. The treatment state (TS) was coded as “1”,
otherwise “0”. The variable indicating the policy implementation in Kentucky was expressed as
an interaction (TS ´ Post) and was coded as “1” after 2012, otherwise “0”, i.e. the difference-indifferences. Population by county (Pop) was included in the analysis. The population was
expressed per 100,000 people. In CDC WONDER data, if the death count is less than 20, those
crude death rates, which are automatically calculated, are shown as ‘unreliable’ (Centers for
Disease Control and Prevention, 2018). Since the death rate was re-calculated with the raw
number, unreliable variable (Unrel) were coded as “1” with all other observations coded as “0”
to control potential reporting bias or other biases due to small observations.
Alcohol sales regulation policy that could be potentially interacting with PDMP was
considered in this analysis. Some states have different alcohol sales regulations among counties.
Kentucky operates by county-level, or even smaller jurisdictions such as towns or cities, based
on votes and categorized dry, wet, and moist. Dry counties do not allow the sale of alcohol at all,
whereas wet counties permit alcohol sales with minimal restrictions uniformly. Besides dry or
wet policies, all the other counties are classified as ‘moist’, which allow the sale of alcohol in
certain designated locations and/or situations (NABCA Research, 2016). This restricted
accessibility to alcohol in dry or moist counties could lower the substitution effect and limit the
alcohol use. Therefore, since the variation of alcohol regulations could affect the outcomes of
interest, alcohol sales policy is included as one of covariates in this research design. Kentucky
Alcoholic Beverage Control kindly provided the voting results of alcohol sales regulations from
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each jurisdiction between 2007 and 2015 and also posted the legal status of each jurisdiction on
their website from 2016 to 2017 (Estep, 2016; Kentucky Alcoholic Beverage Control, 2017).
Unfortunately, because of the limitation of data from CDC WONDER, counties with dry alcohol
policies in Kentucky were not included (i.e., there were too few alcohol-induced deaths in these
Kentucky counties to permit public reporting. This will be discussed below). The alcohol sales
regulations in Missouri counties were uniformly wet policy since 1934 (Missouri Drpartment of
Public Safety, 2019). Uniform alcohol sales policy combined with a lack of state-level PDMP
makes Missouri an excellent candidate to use as a control state. Thus, given the limitations of the
mortality data, moist counties (Alc) were coded as “1”, and wet counties were coded as “0

Statistical Analysis
The regression model of the difference-in-differences design is shown below:
𝑌"#$ = 𝛼' + 𝛼) 𝑇𝑆" + 𝛼, 𝑃𝑜𝑠𝑡$ + 𝛼1 (𝑇𝑆 × 𝑃𝑜𝑠𝑡)"$ + 𝛼5 𝐴𝑙𝑐#$ + 𝛼9 𝑃𝑜𝑝#$ + 𝛼; 𝑈𝑛𝑟𝑒𝑙#$ + 𝑒"#$
The dependent variable 𝑌"#$ , is the measure of alcohol-induced mortality for county j in
state i at year t; 𝛼' is a constant term of this model, representing the expected mean value of 𝑌"#$ .
The covariates mentioned above were all included as independent variables in the model. TS
indicates treatment state i, and Post specifies a post-policy period at year t; 𝛼1 represents the
difference-in-differences estimator, which captures the overall secular trend of alcohol-induced
mortality for state i. Alc, Pop, and Unrel are indicators for the alcohol sales policy, population
per 100,000 people, and unreliable crude death rate, respectively, in county j at year t. The
random unobserved error term is 𝑒"#$ , including all that is omitted or unobserved. The statistical
analysis was executed using Stata v13.1. All the coefficients were estimated through a linear
regression analysis and the estimation is heteroscedasticity-consistent.
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Results
The robust PDMP in Kentucky did not increase alcohol-induced mortality significantly.
The alcohol-induced death rates are higher in Kentucky than in Missouri and are increasing in
both Kentucky and Missouri after the policy change. Nonetheless, there is no evidence to reject
the null hypothesis that the robust PDMP does not increase the alcohol-induced death rates in
Kentucky.

Sample Characteristics
Total 146 counties were observed regarding alcohol-induced mortality in the differencein-differences analysis of the adult population residing in Kentucky and Missouri from 2007 to
2017 (Table 2). In detail, Kentucky observations accounted for 40% (n=58), which is 13 counties
among total 120 counties (11%; Table 3). Counties that were observed each year during the
whole time period were Fayette, Jefferson, and Kenton. These counties include or are located
around big cities, which are Lexington, Louisville, and Cincinnati. Meanwhile, Missouri
amounted to the rest of the observations (60%; n=88), which contained 15 counties out of 114
counties (13%). The most frequently observed counties for 11-year timeframe were Clay,
Greene, Jackson, St. Louis City, and St. Louis, where they are, or they possess, or they are near
big cities such as Kansas City or Springfield. Among these observations, approximately 42% of
the counties (n=61) exhibited unreliable crude death rates. Four Kentucky counties – Hardin
(n=5), Madison (n=1), Pulaski (n=1), and Warren (n=1) – had moist alcohol sales laws for at
least one year in the time period. All the counties that had less than 100,000 residents in both
states had less than 20 alcohol-induced deaths. Some time-points in five counties – Kenton
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(Kentucky), Boone (Missouri, MO), Clay (MO), Jefferson (MO), and St. Charles (MO) –
showed unreliable crude mortalities.

Table 2. The number of counties collected to measure alcohol-induced mortality from 2007
to 2017
Year
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
Total

Kentucky
3
4
7
4
5
5
4
5
6
7
8
58

16

Missouri
6
8
6
5
7
8
9
9
10
10
10
88

Total
9
12
13
9
12
13
13
14
16
17
18
146

Table 3. List of counties involved in the outcome of alcohol-induced mortality from 2007 to
2017
Kentucky Counties
Boone County
Bullitt County
Campbell County
Clark County
Daviess County
Fayette County
Hardin County
Jefferson County
Kenton County
Madison County
Meade County
Pulaski County
Warren County
Total

Frequency
3
2
4
1
6
11
5
11
11
1
1
1
1
58

Missouri Counties
Boone County
Buchanan County
Butler County
Camden County
Cass County
Clay County
Franklin County
Greene County
Jackson County
Jasper County
Jefferson County
Platte County
St. Charles County
St. Louis city
St. Louis County
Total
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Frequency
4
4
2
1
1
11
1
11
11
1
8
2
9
11
11
88

Effect of robust PDMPs on alcohol-induced mortality
In the difference-in-differences model (Table 3; F=22.09; p<0.001), the shift of alcoholinduced mortality after restricting prescription opioid use through mandating PDMP use was not
statistically significant (p>0.05) among adults residing in Kentucky compared to Missouri.

Table 4. Alcohol-induced mortality outcomes of robust PDMP implementation among
adults living in Kentucky (treatment state) compare to Missouri (control state).
Alcohol-Induced Mortality (%)
Covariates
Difference-in-differences
Treatment State (vs. Control State)
Post-Policy (vs. Pre-Policy)
Moist Counties (vs. Wet Counties)
Population (Per 100,000)
Counties with Unreliable Mortality

Estimates
14.49
17.32
16.19
-5.55
-11.85
-34.19

Robust
Standard Error
10.50
7.72*
7.37*
10.06
1.29**
7.05**
*p<0.05, **p<0.001

Change in alcohol-induced mortality from 2007 to 2017
The average mortality in Kentucky was significantly 17.3% higher than Missouri during
the entire time period when other things remain equal (Table 4; p<0.05). As shown in Figure 1,
the average mortality in Kentucky was always higher than Missouri, except the year 2008. The
overall mortality trend was positively associated with time in each state, Kentucky (correlation
coefficient, ρ=0.40) and Missouri (ρ=0.25). When comparing the mortality in both states before
and after the policy change in 2012, the post-policy period had 16.2% higher death rate than the
pre-policy period while everything else stays equal (p<0.05). The counties with moist alcohol
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sales policy did not show any significant results on the mortality change compare to those with
the wet policy. When population in a county increased by 100,000 people, the alcohol-induced
death rate decreased by 11.8% on average while holding other conditions equal (p<0.001). The
counties that had less than 20 count of deaths showed 34.2% lower death rate on average than the
other counties (p<0.001).

Figure 1. Trend in average alcohol-induced mortality among adults living in Kentucky
(treatment state) and Missouri (control state) between 2007 and 2017.

*Kentucky House Bill 1 was implemented in 2012 (red line).
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Discussion
I evaluated the alteration of alcohol-induced mortality after implementing PDMP use
mandate in Kentucky. The finding suggested that the causal effect of comprehensive PDMP in
Kentucky was not statistically significant in changing alcohol-induced deaths among the adult
population. The alcohol-induced mortality in Kentucky was mostly greater than that in Missouri.
Each state had an increase trend in alcohol-induced mortality over time period, therefore, the
mortality in the post-policy period for both states was greater than that in the pre-policy period.
This increase trend of crude mortality corresponds with the national increasing trend since 2010
(Xu, Murphy, Kochanek, Bastian, & Arias, 2018). Regardless of these trends, the trajectory of
outcomes from Kentucky did not diverge significantly from Missouri.
It could be possible that the policy change had an effect on maintaining the status quo of
alcohol-induced mortality. Instead of depending on alcohol use, people could substitute illicit
opioids or other alternative substances. The heterogeneous response toward the policy change
could also generate non-significant result. For example, appropriate pain management guidance
from practitioners using Kentucky PDMP could mute the increase tendency of drug misusers
substituting alcohol for prescription opioids. In addition, migration effect is neglected.
Kentuckians could migrate to Missouri or other neighboring states without robust PDMPs to
obtain prescription opioids without relying on alcohol use. Likewise, moist county residents
could easily migrate to neighboring counties and generate non-significant results versus wet
county residents. The last possible cause is that in both Kentucky and Missouri, deaths by
alcohol have been increasing, and any effects of PDMPs may be difficult to detect within the
increasing trends in both states.
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The control state has several concerns in serving as a counterfactual. One concern is that
Kentucky did operate a PDMP prior to 2012, while Missouri has never had a state-wide PDMP.
It could be better to find another comparison state that had a PDMP similar to Kentucky’s before
2012 and has not implemented robust features. However, without a use mandate, people can
easily find prescribers who do not use the PDMP in order to receive inappropriate prescription
opioids, as was the case prior to KyHB1 adoption when most prescribers did not utilized the
PDMP (Freeman, Goodin, Troske, & Talbert, 2015). Hence, I assumed both Kentucky and
Missouri had non-treated status before 2012. Another concern is about satisfying the common
trend assumption in difference-in-differences design. Apparently in Figure 1, similar trends are
observed between 2009 to 2012, sharing similar upward slopes. Therefore, the common trend
assumption is not violated in this study. One last concern is that PDMP implementation in
Missouri started in 2017 in 43 counties (approximately a third of counties). This started on April
25th among 14 jurisdictions and expanded gradually via those counties (Saint Louis County,
2019). These PDMPs could be negligible since they do not uniformly cover the state, so people
could easily travel to avoid the effect of PDMPs.
Larger population in a county was related to a lower percentage of mortality. This finding
could imply potential urban-rural disparity on alcohol-induced mortality. However, Dixon and
Chartier (2016) reviewed that urban residents tend to use more alcohol than rural residents and
the alcohol use disorder incident trend was similar across the regions. Furthermore, adults older
than 50 living in urban Kentucky presented higher rates of hospitalization caused by concurrent
alcohol and medication use between 2002 and 2012 compare to those in rural area (Zanjani, et
al., 2016).
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Limitations
This study has several limitations. Firstly, the research design might not capture the true
causal effect of policy change. Unobserved or unconsidered variables could be the cause. Drug
abusers could prepare for the policy change, and this is not reflected in this analysis. For
example, they could receive excessive prescription opioids beforehand and use them instead of
substituting alcohol. Accordingly, latency of policy adoption could be longer than the research
design in this study, although the policy compliance rate among practitioners was quite fast.
Another possible cause of the error is that the predicted outcome is too narrow to observe the
hypothesis. For instance, substance misusers might be healthy enough to survive after increasing
alcohol consumption. Also, age-adjusted mortality might be an appropriate outcome measure
instead of the crude rate because age distribution might vary between the counties. Thus, the
crude death rate may not represent the effect of PDMP on alcohol-induced mortality caused by
substituting alcohol for prescription opioid use.
Secondly, the obtained data has several defects. As mentioned above, CDC WONDER
does not rely on the death count less than 20. They considered it as statistically unreliable based
on a relative standard error of 23 percent or more. However, this study was designed by county
with a specific underlying reason, so quite a few counties are likely to have small numbers of
deaths. If a county has low population, the number of deaths less than 20 could be meaningful.
Thus, I re-calculated the mortality with raw data and included those counties labeled unreliable.
Moreover, because of confidentiality constraints, they suppressed the data when the count is less
than 10 (Centers for Disease Control and Prevention, 2018). Consequently, the amount of data
obtained was less than the actual state overall counts. The state-level death counts were much
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greater than what I actually extracted. Therefore, a selection bias threat exists because higher
population counties are more likely to be posted.
Thirdly, this study did not account for some policies that could affect the result. KyHB1
included a pain management facility regulation in addition to the use mandate. The PDMP could
encompass abusive prescription behaviors from those clinics, but it is difficult to account on the
sole effect of PDMP. Also, alcohol-related tax policies are not included, which are another factor
causing behavior change in alcohol use.
Finally, this analysis cannot be generalized to other states, nation-wide level, individuallevel, or population under age 18. Also, it does not present long-term effect of the policy change.
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Conclusion and Policy Recommendation
In conclusion, prescription opioid access restriction did not have a statistically significant
substitution effect of alcohol-induced mortality among adults. This is one of the first studies
assessing adverse events of PDMPs, especially about unintended consequences of alcoholinduced death. In addition, this analysis did not find alcohol sales policy to be a significant
variable in evaluating the relationship between the program and alcohol-induced mortality.
For these reasons, I recommend retaining the mandate use feature in Kentucky PDMP
and evaluating the findings with further studies as follow:
•

Evaluate using other outcomes such as age-adjusted mortality, morbidity, and
drunken driving caused deaths/crashes.

•

Analyze using individual-level deidentified death report data.

•

Expand the range of population (adolescent) and region (other states with mandatory
use laws).

•

Assess long-term effects of PDMPs on alcohol-related outcomes.

•

Investigate potential urban-rural disparities on alcohol-related outcomes after
adopting the revised PDMP in Kentucky.
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